The amyloid cascade and Alzheimer’s disease therapeutics: theory versus observation

Clinical Trials for Disease-Modifying Therapies in Alzheimer’s Disease: A Primer, Lessons Learned, and a Blueprint for the Future

(2018) Jeffrey Cummings et al.   JOURNAL OF ALZHEIMERS DISEASE

The Amyloid-β Oligomer Hypothesis: Beginning of the Third Decade

(2018) Erika N. Cline et al.   JOURNAL OF ALZHEIMERS DISEASE

The Aβ protofibril selective antibody mAb158 prevents accumulation of Aβ in astrocytes and rescues neurons from Aβ-induced cell death

(2018) Sofia Söllvander et al.   Journal of Neuroinflammation

Alzheimer's disease: The right drug, the right time

(2018) Todd E. Golde et al.   SCIENCE

Why do trials for Alzheimer’s disease drugs keep failing? A discontinued drug perspective for 2010-2015

(2017) Dev Mehta et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer’s Disease Patients

(2017) Nzeera Ketter et al.   JOURNAL OF ALZHEIMERS DISEASE

Mechanisms of recognition of amyloid-β (Aβ) monomer, oligomer, and fibril by homologous antibodies

(2017) Jun Zhao et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Amyloid β oligomers (AβOs) in Alzheimer’s disease

(2017) Barbara Mroczko et al.   JOURNAL OF NEURAL TRANSMISSION

A phase 3 trial of IV immunoglobulin for Alzheimer disease

(2017) Norman R. Relkin et al.   NEUROLOGY

Semagacestat Is a Pseudo-Inhibitor of γ-Secretase

(2017) Shinji Tagami et al.   Cell Reports

Structural and Chemical Biology of Presenilin Complexes

(2017) Douglas S. Johnson et al.   Cold Spring Harbor Perspectives in Medicine

Dura mater is a potential source of Aβ seeds

(2016) Gabor G. Kovacs et al.   ACTA NEUROPATHOLOGICA

Apolipoprotein E as a Therapeutic Target in Alzheimer’s Disease: A Review of Basic Research and Clinical Evidence

(2016) Yu Yamazaki et al.   CNS DRUGS

The amyloid hypothesis of Alzheimer's disease at 25 years

(2016) Dennis J Selkoe et al.   EMBO Molecular Medicine

AZD3293: Pharmacokinetic and Pharmacodynamic Effects in Healthy Subjects and Patients with Alzheimer’s Disease

(2016) Gvido Cebers et al.   JOURNAL OF ALZHEIMERS DISEASE

Biomarker Exposure-Response Analysis in Mild-To-Moderate Alzheimer’s Disease Trials of Bapineuzumab

(2016) Alberto Russu et al.   JOURNAL OF ALZHEIMERS DISEASE

Discovery of the 3-Imino-1,2,4-thiadiazinane 1,1-Dioxide Derivative Verubecestat (MK-8931)–A β-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibitor for the Treatment of Alzheimer’s Disease

(2016) Jack D. Scott et al.   JOURNAL OF MEDICINAL CHEMISTRY

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

(2016) Jeff Sevigny et al.   NATURE

Distinct prion-like strains of amyloid beta implicated in phenotypic diversity of Alzheimer's disease

(2016) Mark Cohen et al.   Prion

The BACE1 inhibitor verubecestat (MK-8931) reduces CNS  -amyloid in animal models and in Alzheimers disease patients

(2016) M. E. Kennedy et al.   Science Translational Medicine

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

(2016) Veronika Logovinsky et al.   Alzheimers Research & Therapy

Rapidly progressive Alzheimer’s disease features distinct structures of amyloid-β

(2015) Mark L. Cohen et al.   BRAIN

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

(2014) Eric Karran et al.   ANNALS OF NEUROLOGY

Autophagy and Its Normal and Pathogenic States in the Brain

(2014) Ai Yamamoto et al.   Annual Review of Neuroscience

Apolipoprotein E in Alzheimer's Disease: An Update

(2014) Jin-Tai Yu et al.   Annual Review of Neuroscience

Amyloid-ß-directed immunotherapy for Alzheimer's disease

(2014) L. Lannfelt et al.   JOURNAL OF INTERNAL MEDICINE

Targeting the β secretase BACE1 for Alzheimer's disease therapy

(2014) Riqiang Yan et al.   LANCET NEUROLOGY

ApoE and Aβ in Alzheimer’s Disease: Accidental Encounters or Partners?

(2014) Takahisa Kanekiyo et al.   NEURON

Soluble Aβ Oligomers Are Rapidly Sequestered from Brain ISF In Vivo and Bind GM1 Ganglioside on Cellular Membranes

(2014) Soyon Hong et al.   NEURON

Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease

(2014) Stephen Salloway et al.   NEW ENGLAND JOURNAL OF MEDICINE

Perspectives on future Alzheimer therapies: amyloid-β protofibrils - a new target for immunotherapy with BAN2401 in Alzheimer’s disease

(2014) Lars Lannfelt et al.   Alzheimers Research & Therapy

Apolipoprotein E, gender, and Alzheimer’s disease: an overlooked, but potent and promising interaction

(2013) Leo Ungar et al.   Brain Imaging and Behavior

Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease

(2013) Jean-Charles Lambert et al.   NATURE GENETICS

A Phase 3 Trial of Semagacestat for Treatment of Alzheimer's Disease

(2013) Rachelle S. Doody et al.   NEW ENGLAND JOURNAL OF MEDICINE

Amyloid-beta oligomerization in Alzheimer dementia versus high-pathology controls

(2012) Thomas J. Esparza et al.   ANNALS OF NEUROLOGY

Cerebrospinal fluid APOE levels: an endophenotype for genetic studies for Alzheimer's disease

(2012) Carlos Cruchaga et al.   HUMAN MOLECULAR GENETICS

First and Second Generation γ-Secretase Modulators (GSMs) Modulate Amyloid-β (Aβ) Peptide Production through Different Mechanisms

(2012) Tomas Borgegard et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Small-Molecule Structure Correctors Target Abnormal Protein Structure and Function: Structure Corrector Rescue of Apolipoprotein E4–Associated Neuropathology

(2012) Robert W. Mahley et al.   JOURNAL OF MEDICINAL CHEMISTRY

Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature

(2012) Peter T. Nelson et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes

(2012) Iryna Benilova et al.   NATURE NEUROSCIENCE

A Plaque-Specific Antibody Clears Existing β-amyloid Plaques in Alzheimer's Disease Mice

(2012) Ronald B. DeMattos et al.   NEURON

Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology

(2012) Robert W. Mahley et al.   NEURON

The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain

(2011) Tsuyoshi Hamaguchi et al.   ACTA NEUROPATHOLOGICA

Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup

(2011) Reisa A. Sperling et al.   Alzheimers & Dementia

Tramiprosate in mild-to-moderate Alzheimer’s disease – a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)

(2011) Paul S. Aisen et al.   Archives of Medical Science

High ability of apolipoprotein E4 to stabilize amyloid-β peptide oligomers, the pathological entities responsible for Alzheimer's disease

(2011) Emilie Cerf et al.   FASEB JOURNAL

Brain Oligomeric β-Amyloid but Not Total Amyloid Plaque Burden Correlates With Neuronal Loss and Astrocyte Inflammatory Response in Amyloid Precursor Protein/Tau Transgenic Mice

(2011) Bibiana DaRocha-Souto et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Soluble A  Seeds Are Potent Inducers of Cerebral  -Amyloid Deposition

(2011) F. Langer et al.   JOURNAL OF NEUROSCIENCE

Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study

(2011) Melissa E Murray et al.   LANCET NEUROLOGY

The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics

(2011) Eric Karran et al.   NATURE REVIEWS DRUG DISCOVERY

Measurement of anti-beta amyloid antibodies in human blood

(2010) Paul Szabo et al.   JOURNAL OF NEUROIMMUNOLOGY

Human intravenous immunoglobulin provides protection against Aβ toxicity by multiple mechanisms in a mouse model of Alzheimer's disease

(2010) Johanna Magga et al.   Journal of Neuroinflammation

Investigation of the noncovalent interactions between anti-amyloid agents and amyloid β peptides by ESI-MS

(2010) Eric Martineau et al.   JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY

Long-Term Follow-Up of Patients Immunized with AN1792: Reduced Functional Decline in Antibody Responders

(2009) Bruno Vellas et al.   Current Alzheimer Research

Effect of Tarenflurbil on Cognitive Decline and Activities of Daily Living in Patients With Mild Alzheimer DiseaseA Randomized Controlled Trial

(2009) Robert C. Green   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Apolipoprotein E and its receptors in Alzheimer's disease: pathways, pathogenesis and therapy

(2009) Guojun Bu   NATURE REVIEWS NEUROSCIENCE

IV immunoglobulin is associated with a reduced risk of Alzheimer disease and related disorders

(2009) H. Fillit et al.   NEUROLOGY

A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease

(2009) S. Salloway et al.   NEUROLOGY

Structure-neurotoxicity relationships of amyloid  -protein oligomers

(2009) K. Ono et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Oligomeric amyloid   associates with postsynaptic densities and correlates with excitatory synapse loss near senile plaques

(2009) R. M. Koffie et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Active and Passive Immunotherapy for Neurodegenerative Disorders

(2008) David L. Brody et al.   Annual Review of Neuroscience

Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease

(2008) Adam S. Fleisher et al.   ARCHIVES OF NEUROLOGY

Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial

(2008) Clive Holmes et al.   LANCET

Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory

(2008) Ganesh M Shankar et al.   NATURE MEDICINE

ApoE Promotes the Proteolytic Degradation of Aβ

(2008) Qingguang Jiang et al.   NEURON

Peripheral and central biodistribution of 111In-labeled anti-beta-amyloid autoantibodies in a transgenic mouse model of Alzheimer's disease

(2008) Michael Bacher et al.   NEUROSCIENCE LETTERS

Tauopathy in human and experimental variant Creutzfeldt-Jakob disease

(2007) G. Giaccone et al.   NEUROBIOLOGY OF AGING